Table 1 Baseline patient characteristics with respect to IKZF1 mutation status.
From: Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
Parameter | IKZF1 mutated | IKZF1 wildtype | p |
|---|---|---|---|
n/N (%) | 45/1606 (2.8) | 1561/1606 (97.2) | |
Age (years), median (IQR) | 52 (43–64) | 56 (45–66) | 0.501 |
Sex, n (%) | 0.762 | ||
Female | 20 (44.4) | 748 (47.9) | |
Male | 25 (55.6) | 813 (52.1) | |
Disease status, n (%) | |||
de novo | 32 (71.1) | 1307 (83.7) | 0.038 |
sAML | 9 (20.0) | 186 (11.9) | 0.107 |
tAML | 2 (4.4) | 52 (3.3) | 0.662 |
Missing | 2 (4.4) | 61 (3.9) | |
Extramedullary disease, n (%) | 10 (22.2) | 204 (13.1) | 0.116 |
missing | 3 (6.7) | 137 (8.8) | |
ELN-Risk 2022, n (%) | |||
Favorable | 10 (22.2) | 566 (36.3) | 0.079 |
Intermediate | 8 (17.8) | 411 (26.3) | 0.297 |
Adverse | 26 (57.8) | 567 (36.3) | 0.004 |
Missing | 1 (2.2) | 17 (1.1) | |
Complex karyotype, n (%) | 0.479 | ||
No | 36 (80.0) | 1283 (82.2) | |
Yes | 7 (15.6) | 181 (11.6) | |
Missing | 2 (4.4) | 97 (6.2) | |
Normal karyotype, n (%) | 0.003 | ||
No | 29 (64.5) | 644 (41.3) | |
Yes | 14 (31.1) | 819 (52.4) | |
Missing | 2 (4.4) | 98 (6.3) | |
Allogeneic stem cell transplantation | |||
In first CR | 6 (13.3) | 238 (15.2) | 0.836 |
As salvage therapy | 10 (22.2) | 213 (13.6) | 0.123 |
Other | 2 (4.4) | 50 (3.2) | 0.655 |
Missing | 0 | 0 | |
Laboratory, median (IQR) | |||
WBC (109/l) | 17.8 (5.0–43.0) | 19.1 (4.4–53.7) | 0.590 |
HB (mmol/l) | 5.3 (4.7–6.7) | 5.9 (5.1–7.0) | 0.036 |
PLT (109/l) | 35 (25–80) | 51 (28–95) | 0.029 |
LDH (U/l) | 523.2 (287.0–751.0) | 443.7 (281.0–778.0) | 0.694 |
PBB (%) | 45.5 (16.5–81.0) | 40.0 (12.0–73.0) | 0.150 |
BMB (%) | 65.0 (43.0–80.5) | 63.0 (44.0–79.0) | 0.997 |
